Resolution peptide ends phase-I tests
A new peptide-based radiopharmaceutical for detecting inflammatorydisease that is under development by Resolution Pharmaceuticalshas finished phase-I clinical testing, the company reported lastmonth. The technetium-labeled agent, RP128, performed as
A new peptide-based radiopharmaceutical for detecting inflammatorydisease that is under development by Resolution Pharmaceuticalshas finished phase-I clinical testing, the company reported lastmonth. The technetium-labeled agent, RP128, performed as expectedin tests conducted at the Free University of Brussels in Belgium,according to John Thornback, general manager of Mississauga, Ontario-basedResolution.
The company plans to begin phase-II clinical tests in the firstquarter to compare the performance of RP128 against other proceduresfor diagnosing inflammation. It also hopes to determine whichtypes of inflammatory disease the agent is most suited for, Thornbacksaid.
Resolution Pharmaceuticals is a joint venture between AllelixBiopharmaceuticals and Canadian radiopharmaceutical company NordionInternational. It began operations in 1993 and RP128 is its leadproduct, with other peptide-based imaging agents under development.The firm is planning a private stock placement shortly, Thornbacksaid.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.
